7月14日，Tempus AI盘中下跌5.05%，报55.285美元/股，成交额1.73亿美元。近期利空因素持续发酵，股价延续跌势。
消息面上，Biovica International AB此前宣布终止与Tempus AI的合作协议，明确表示双方合作未能促成产品商业化或产生任何收入。此外，公司CEO兼董事长Eric Lefkofsky于6月底通过10b5-1计划合计减持约126,250股，成交价区间54.82至59.59美元。Freedom Capital Markets近期给予公司持有评级，目标价59美元，当前股价已大幅低于该目标位。公司将于7月30日发布第二季度财报，市场预期每股亏损0.41美元，盈利修复前景不确定性叠加上述利空，加剧了投资者抛售情绪。
Tempus AI通过人工智能在医疗保健领域的实际应用，致力于释放精准医疗的力量，将实验室结果与患者临床数据连接，使诊断测试更加智能化和个性化。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.